The Latest Report on APS Treatment Research and Recommendations is Released
A newly published report shares the latest in antiphospholipid antibody syndrome (APS) treatments, from existing therapies to potential new drugs on the horizon. APS, a blood disorder that can cause life-threatening blood clots and serious pregnancy complications, is a common co-occurring disease among people with lupus. It is also a complex and challenging disorder to treat.
The review was conducted by the 16th International Congress on Antiphospholipid Antibodies Task Force on APS Treatment Trends. The task force reviewed the latest developments in APS treatment research and found the following treatments may be beneficial:
- Direct oral anticoagulants
- Low-dose aspirin
- Vitamin D
- Anti-TNF therapy
- Anti-complement therapy
The task force also identified a few new therapeutic approaches that have only recently demonstrated potential efficacy in APS treatment and require further investigation, such as:
- Coenzyme Q10 (CoQ10)
- Adenosine-targeting treatments
- Drugs targeting antibody-producing cells
- Anti-interferon therapies
The latest report underscores the need for continued clinical trials for APS, and the task force recommends the increased development of international registries, prospective cohort studies and randomized control trials to meaningfully advance APS treatment. Consult your physician before making any changes to your medications. Learn more about antiphospholipid antibody syndrome (APS).